Michael Lenertz, DPM
Foot & Ankle Surgery · Paris, TXNPI 1205936481
Payments from drug & device makers
Across 64 payments — averaging $131.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pylant Medical$4K
- Arthrex$3K
- Paragon 28, Inc.$330
- Smith+Nephew$120
- Vaporox, Inc.$100
- Stryker$63
- plus $299 from 13 others
What the payments were for
- Travel & lodging$1,30816%
- Food & beverage$1,59419%
- Education$5,48365%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pylant Medical | 18 | $4,476 |
| Arthrex | 18 | $2,996 |
| Paragon 28, Inc. | 3 | $330 |
| Smith+Nephew | 6 | $120 |
| Vaporox, Inc. | 1 | $100 |
| Stryker | 2 | $63 |
| Kerecis Limited | 2 | $46 |
| Mimedx Group, Inc. | 1 | $40 |
| Nevro Corp. | 1 | $32 |
| Cashflow Solutions, LLC | 2 | $30 |
| Aroa Biosurgery Incorporated | 2 | $27 |
| Solventum Corporation | 1 | $21 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
| Neuros Medical, Inc. | 1 | $18 |
| Organogenesis Inc. | 1 | $16 |
| Orthofix Medical, Inc. | 1 | $14 |
| Integra Lifesciences Corporation | 1 | $14 |
| Bioventus LLC | 1 | $12 |
| Glenmark Therapeutics Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,385 in reported general payments places this provider in the 65th percentile of 684 foot & ankle surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Itraconazole | 13 | $903 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 32 | $663 |
| Gabapentin | 49 | $541 |
| Pregabalin | 18 | $462 |
| Doxycycline Hyclate | 34 | $358 |
| Ciclopirox | 14 | $245 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 22 | $220 |
| Allopurinol | 11 | $197 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 31 | $182 |
| Cephalexin | 30 | $172 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 17 | $143 |
| Meloxicam | 42 | $91 |
| Clindamycin Hcl | 12 | $59 |
Paid to pharmacies, not to this prescriber.
Other foot & ankle surgery in Paris
- Richard PollakSan Antonio$6.1M
- Joseph CaporussoMcAllen$6M
- Mark DaltonAustin$4.1M
- William McGarveyKaty$3.5M
- Eugene CurryDallas$3.1M
- Chad HowzeSan Antonio$2.4M
- Graham HamiltonEdinburg$2.1M
- Kevin VarnerHouston$1.1M
- Paul KimDallas$972K
- Mark RobsonAustin$957K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.